<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92560">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02083354</url>
  </required_header>
  <id_info>
    <org_study_id>200104</org_study_id>
    <nct_id>NCT02083354</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 E/K Mutation-Positive Acral Lentiginous Melanoma</brief_title>
  <official_title>An Open-Label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 E/K Mutation-Positive Acral Lentiginous Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Europe: European Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, multi-center, Phase II study to evaluate dabrafenib and
      trametinib combination therapy in subjects with BRAF V600-E/K mutation-positive,
      unresectable or metastatic Acral lentiginous melanoma (ALM).  This study will evaluate the
      objective response rate (ORR), progression free survival (PFS), duration of response,
      overall survival (OS), safety and efficacy, to assess single-dose (Chinese subjects only)
      and steady state (all subjects) exposure to dabrafenib, dabrafenib metabolites, and
      trametinib and characterize the population pharmacokinetics (PK) and pharmacodynamics (PD)
      of dabrafenib and trametinib.  Approximately 35 subjects (20 subjects in stage 1 and
      additional 15 subjects in stage 2) will be enroled and will receive dabrafenib 150 milligram
      (mg) orally twice daily and trametinib 2 mg orally once daily.  Treatment will continue
      until disease progression, death, unacceptable toxicity, or withdrawal of consent, or study
      closure. After treatment discontinuation, subjects will be followed for survival and disease
      progression as applicable.  Survival and new anti-cancer therapy follow-up will continue
      until 70% of the total enroled population has died or been lost to follow-up. At such time
      the study will be closed
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine ORR of dabrafenib in combination with trametinib in subjects with BRAF V600E/K mutation-positive, unresectable or metastatic ALM.  ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the antitumor activity by assessing the progression-free survival (PFS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS defined as the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the antitumor activity by assessing the duration of response</measure>
    <time_frame>Up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of response is defined as the time from first documented evidence of CR or PR until the earliest date of documented radiological progression or death due to any cause among subjects who achieved a confirmed CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the antitumor activity by assessing the overall survival (OS)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS defined as the interval from first dose of study treatment to the date of death, irrespective of the cause of death; subjects still alive will be censored at the date of the last contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess single dose (Chinese subjects only) and steady state (all subjects) exposures to dabrafenib, dabrafenib metabolites, and trametinib, and characterize the population pharmacokinetics of dabrafenib and trametinib</measure>
    <time_frame>Pre-dose (within 30 minutes prior to dosing) and 1, 2, 4, 6, and 8 hours after dosing on Day 15.  For subjects in China: Pre-dose (within 30 minutes prior to dosing) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours after dosing on Day 1 and Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters will include maximum peak concentration (Cmax), Time to Cmax (tmax), Predose concentration (Ctau), Area under the concentration-time curve (AUC) from time 0 to last time of quantifiable concentration (AUC [0-t]), and from time 0 to 8 hours of quantifiable concentration (AUC[0-8]); AUC from time 0 to 12 hours of quantifiable concentration (AUC[0-12]) (dabrafenib and metabolites only), AUC (0-24) (trametinib only) and the metabolite to dabrafenib ratio of AUC(0-t). Population PK parameters will include, apparent clearance following oral dosing (CL/F), volume of distribution (V/F), and absorption rate constant (Ka) for dabrafenib and trametinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of dabrafenib and trametinib as assessed by Physical examinations</measure>
    <time_frame>Screening, every 4 weeks and at treatment discontinuation (approximately 1 year but can be up to 5 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete physical examination will include assessments of eyes, neurological and cardiovascular systems, lungs, abdomen, and any other areas with signs and symptoms of disease, and of the head, neck, ears, nose, mouth, throat, thyroid, lymph nodes, extremities, and a full skin exam to assess cutaneous malignancies and proliferative skin diseases. Also, thorough genitourinary (pelvic) and rectal examinations to assess secondary malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of dabrafenib and trametinib as assessed by vital signs</measure>
    <time_frame>Screening, every 4 weeks and at treatment discontinuation (approximately 1 year but can be up to 5 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vital sign measurements will include systolic and diastolic blood pressure, body temperature, pulse rate, body weight, and height (only at Screening)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of dabrafenib and trametinib as assessed by 12-lead electrocardiograms (ECG), echocardiogram (ECHO)</measure>
    <time_frame>ECG Screening, Day 15,  Week 4, 8 and 12, every 12 weeks after Week 12 and treatment Discontinuation(approximately 1 year but can be up to 5 years).  ECHO Screening, Week 4 and every 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical assessments including 12-lead (ECG, ECHO will be done to assess cardiac safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of dabrafenib and trametinib as assessed by eye examinations</measure>
    <time_frame>Screening and Week 4 and as clinically warranted</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety as measured by clinical assessments including eye exams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of dabrafenib and trametinib by laboratory assessments</measure>
    <time_frame>Screening, every 4 weeks and at treatment Discontinuation (approximately 1 year but can be up to 5 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Laboratory assessments will include clinical chemistry and hematology parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of dabrafenib and trametinib as assessed adverse events (AEs)</measure>
    <time_frame>From the first dose of study treatment until 30 days after discontinuation of study treatment (approximately 1 year but can be up to 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day.  The second dose of dabrafenib (150 mg) alone will be administered approximately 12 hours after the morning dose.  Subjects will continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Dabrafenib will be provided as 50 mg and 75 mg capsules.  Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.  Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent, which includes compliance with the requirements and
             restrictions listed in the consent form.

          -  &gt;=18 years of age.

          -  Histologically confirmed acral lentiginous melanoma that is either Stage IIIC
             (unresectable) or Stage IV (metastatic), and BRAF V600E/K mutation-positive. Note:
             BRAF V600E/K mutation status for study eligibility should be determined using direct
             sequencing or PCR method. The test will be conducted at a GSK designated central
             laboratory. If data warrants the development of a companion diagnostic assay, the
             screening tissue may be subject to additional testing of BRAF mutations.

          -  Measurable disease (i.e., present with at least one measurable lesion) by RECIST
             version1.1.

          -  Performance status score of 0 or 1 according to the Eastern Cooperative Oncology
             Group (ECOG) scale.

          -  All prior anti-cancer treatment-related toxicities (except alopecia and laboratory
             values) must be &lt;=Grade 1 according to the Common Terminology Criteria for Adverse
             Events version 4 (CTCAE version 4.0) at the time of enrolment.

          -  Able to swallow and retain oral medication and must not have any clinically
             significant gastrointestinal abnormalities that may alter absorption such as
             malabsorption syndrome or major resection of the stomach or bowels.

          -  Women of child-bearing potential must have a negative serum pregnancy test within 7
             days of first dose of study treatment and agree to use effective contraception, from
             14 days prior to enrolment, throughout the treatment period and for 4 months after
             the last dose of study treatment.

          -  Adequate baseline organ function as defined below: Absolute Neutrophil Count:&gt;= 1.2 Ã—
             10^9/liter (L); Hemoglobin: &gt;=9 grams (g)/deciliter (dL); Platelet count: &gt;=75 x
             10^9/L; Prothrombin Time/International Normalized Ratio (INR) (Subjects receiving
             anticoagulation treatment may be allowed to participate with INR established within
             the therapeutic range prior to enrolment) and Partial Thromboplastin Time: &lt;=1.5 x
             Upper Limit of Normal (ULN); Albumin: &gt;=2.5 g/dL; Total bilirubin: &lt;=1.5 x ULN;
             Aspartate aminotransferase and Alanine aminotransferase: &lt;=2.5 x ULN; Calculated
             creatinine clearance (Calculate creatinine clearance using standard Cockcroft-Gault
             formula): &gt;=50 milliliter (mL)/ minute (min); Left Ventricular Ejection Fraction
             (LVEF) (ECHO scans must be used throughout the study) : &gt;= Lower limit of normal
             (LLN) by ECHO.

        Exclusion Criteria:

          -  Known non-acral lentiginous cutaneous, mucosal or ocular melanoma.

          -  Prior treatment with a BRAF inhibitor (including but not limited to dabrafenib,
             vemurafenib, LGX818, and XL281/BMS-908662) or a MEK inhibitor (including but not
             limited to trametinib, AZD6244, and RDEA119).

          -  Prior systemic anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy,
             vaccine therapy, or investigational treatment) for Stage IIIC (unresectable) or Stage
             IV (metastatic) ALM. Prior systemic treatment in the adjuvant setting is allowed.
             (Note: Ipilimumab treatment must end at least 8 weeks prior to enrolment.).

          -  Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity,
             biologic therapy, or immunotherapy within 21 days prior to enrolment /or daily or
             weekly chemotherapy without the potential for delayed toxicity within 14 days prior
             to enrolment.

          -  Taken an investigational drug within 28 days or 5 half-lives (minimum 14 days),
             whichever is shorter, prior to enrolment.

          -  Current use of a prohibited medication.

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to the study treatments, their excipients, and/or dimethyl
             sulfoxide (DMSO).

          -  Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C
             Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection
             which are allowed).

          -  Brain metastasis are excluded unless: All known lesions have been definitively
             treated with surgery or stereotactic surgery (whole-brain radiation may be given as
             adjuvant treatment), OR Brain lesion(s), if still present, must be confirmed stable
             (i.e., no increase in lesion size) for &gt;=12 weeks prior to enrolment (stability must
             be confirmed with two consecutive magnetic resonance image (MRI) or computed
             tomography (CT) scans with contrast, separated by &gt;6 weeks AND Asymptomatic with no
             corticosteroid requirements for &gt;=4 weeks prior to enrolment, AND No enzyme inducing
             anticonvulsants for &gt;=2 weeks prior to enrolment. In addition, for subjects that had
             brain metastases but currently have no evidence of disease (NED), NED for &gt;=12 weeks
             is required and must be confirmed by two consecutive scans, separated by &gt;=6 weeks,
             prior to randomization.

          -  History of another malignancy. Exception: Subjects who have been disease-free for 3
             years, (i.e. subjects with second malignancies that are indolent or definitively
             treated at least 3 years ago), or subjects with a history of completely resected
             non-melanoma skin cancer.

          -  A history or evidence of cardiovascular risk including any of the following: Current
             LVEF &lt; Institutional LLN; A QTc interval corrected for heart rate &gt;=480 millisecond
             (msec) (using Bazett's formula); A history or evidence of current clinically
             significant uncontrolled arrhythmias. Exception: Subjects with atrial fibrillation
             controlled for &gt;30 days prior to enrolment are eligible; A history (within 6 months
             prior to enrolment) of acute coronary syndromes (including myocardial infarction or
             unstable angina), coronary angioplasty; A history or evidence of current &gt;=Class II
             congestive heart failure as defined by the New York Heart Association (NYHA)
             guidelines; Treatment refractory hypertension defined as a blood pressure of systolic
             &gt;140 millimeters of mercury (mmHg) and/or diastolic &gt;90 mmHg which cannot be
             controlled by anti-hypertensive therapy; Subjects with intra-cardiac defibrillators
             or permanent pacemakers; Known cardiac metastases; Abnormal cardiac valve morphology
             (&gt;=grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e.,
             mild regurgitation/stenosis] can be entered on study). Subjects with moderate
             valvular thickening should not be entered on study.

          -  Uncorrectable electrolyte abnormalities (e.g. hypokalaemia, hypomagnesaemia,
             hypocalcaemia determined by blood chemistry), long QT syndrome or taking medicinal
             products known to prolong the QT interval.

          -  A history or current evidence/risk of retinal vein occlusion (RVO) or central serous
             retinopathy (CSR) including: Presence of predisposing factors to RVO or CSR (e.g.,
             uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled
             diabetes mellitus, or a history of hyperviscosity or hypercoagulability syndromes);
             or Visible retinal pathology as assessed by ophthalmic examination that is considered
             a risk factor for RVO or CSR such as: Evidence of new optic disc cupping; Evidence of
             new visual field defects on automated perimetry; Intraocular pressure &gt;21 mmHg as
             measured by tonography.

          -  Any serious or unstable pre-existing medical conditions (aside from malignancy
             exceptions specified above), psychiatric disorders, or other conditions that could
             interfere with the subject's safety, obtaining informed consent, or compliance with
             study procedures.

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to the study treatments, their excipients, and/or DMSO.

          -  Pregnant or nursing females.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dabrafenib</keyword>
  <keyword>acral lentiginous melanoma</keyword>
  <keyword>trametinib</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
